$JAZZ News

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial

Jazz Pharmaceuticals Shares May Have Room for Further Appreciation, RBC Says

Will Ziihera’s First‑Line HER2‑Positive GEA Approval Change Jazz Pharmaceuticals’ (JAZZ) Oncology Narrative

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Jazz Pharmaceuticals Announces Private Offering Of $1B Of Exchangeable Senior Notes Due 2032; Expects To Repurchase Up To $225M Of Stock From Note Buyers In Privately Negotiated Transactions

Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $310

Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA

Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA - Slideshow